Additional Paid-In Capital Equity Components [Axis] Retained Earnings / Accumulated Deficit Other Comprehensive Income / Loss Common Stock [Member] Series A Preferred Stock [Member] Class of Stock [Axis] Series B Preferred Stock [Member] Private Placement [Member] Sale of Stock [Axis] Minimum [Member] Range [Axis] Share Purchase Warrants[Member] Maximum [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Carrying Value [Member] Fair Value [Member] SharePurchaseWarrants[Member] ConversionOption[Member] Convertible Notes Payable 22 [Member] Debt Instrument [Axis] Convertible note [Member] Convertible Note1 [Member] Convertible Note2 [Member] Convertible Note3 [Member] Convertible Note4 [Member] Convertible Note5 [Member] Convertible Note6 [Member] Convertible Note7 [Member] Convertible Note8 [Member] Convertible Note9 [Member] Convertible Note10 [Member] Convertible Note11 [Member] Convertible Note12 [Member] Convertible Note13 [Member] Convertible Note14 [Member] Convertible Note15 [Member] Convertible Note16 [Member] Convertible Note17 [Member] Convertible Note18 [Member] Convertible Note19 [Member] Convertible Notes I [Member] Convertible Notes II [Member] Preferred stock OIfficer and Director [Member] Title of Individual [Axis] Series A Warrant [Member] January 12, 2015 [Member] Report Date [Axis] Series B Warrant [Member] Series C Warrant [Member] Series D Warrant [Member] Series E Warrant [Member] March 9, 2015 [Member] March 2014 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Statement [Table] Statement [Line Items] ASSETS Current Assets Cash Prepaid expenses and deposits Deferred financing costs Total Current Assets LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current Liabilities Accounts payable and accrued liabilities Research agreement obligations Derivative liability - conversion option Derivative liability - warrants Convertible notes payable Loans payable, related party (2013 - $5,200) Promissory notes, related party Due to related parties Total Current Liabilities COMMITMENTS AND CONTINGENCIES Stockholders’ Equity (Deficit) Convertible preferred stock value Common stock, $0.001 par value, 500,000,000 shares authorized 20,318,815 shares issued and outstanding (2013 - 1,465,712) Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Total Stockholders’ Equity (Deficit) Total Liabilities and Stockholders’ Equity (Deficit) Common stock par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Convertible preferred stock par value Convertible preferred stock authorized Convertible preferred stock shares designated Convertible preferred stock, issued Convertible preferred stock, outstanding Loans payable, related party Income Statement [Abstract] Operating expenses: General and administrative Research and development Loss from Operations Other Income (Expense) Foreign exchange (loss) gain Changes in fair value of derivative liabilities Accretion of discount on convertible notes Interest and finance charges Loss on extinguishment of debt Loss on lawsuit Net Loss for the Period Other comprehensive income Foreign exchange translation adjustment TOTAL COMPREHENSIVE LOSS Basic and Diluted Net Loss per Share Weighted Average Number of Common Shares Outstanding Balance Balance, Amount Notes converted into shares Notes converted into shares, Amount Stock based compensation Obligation to issue shares at fair value pursuant to service agreements Issued at fair value pursuant to debt settlement agreements Issued at fair value pursuant to debt settlement agreements, Amount Finders’ fee Issued at fair value pursuant to service agreements Issued at fair value pursuant to service agreements, Amount Shares issued for director compensation Shares issued for director compensation, Amount Non-cash exercise of warrants Non-cash exercise of warrants, Amount Foreign exchange translation adjustment Net loss Convertible notes, promissory notes, loan payable-related party, due to related parties and accrued interest converted into Series A and B preferred stock and immediately converted into commons stock Convertible notes, promissory notes, loan payable-related party, due to related parties and accrued interest converted into Series A and B preferred stock and immediately converted into commons stock, Amount Conversion of accounts payable to common stock Conversion of accounts payable to common stock, Amount Private placement (net of finders’ fee) Private placement (net of finders’ fee), Amount Fair value of warrants recognized as derivative liabilities Balance Balance, Amount Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash from operating activities: Changes in fair value of derivative liabilities Loss on extinguishment of debt Accretion of discount on convertible notes Non-cash interest and finance charges Stock based compensation Foreign exchange loss Changes in operating assets and liabilities: Prepaid expenses and deposits Deferred financing costs Accounts payable and accrued liabilities Research agreement obligations NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Issuance of shares, net of issuance costs of $387,500 Convertible notes issuance Proceeds from loans payable Repayment to related parties Repayment of convertible notes Repayment of promissory notes NET CASH PROVIDED BY FINANCING ACTIVITIES INCREASE IN CASH CASH, BEGINNING OF YEAR CASH, END OF YEAR SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES Accounts payable settled in common stock Conversion of debt obligations into common stock: Accrued interest Convertible notes payable Loans payable, related party Promissory notes, related party Due to related parties Fair value derivative liability - conversion option at conversion Net of issuance costs Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS BASIS OF PRESENTATION LIQUIDITY AND FINANCIAL CONDITION Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes to Financial Statements POTENTIALLY DILUTIVE SECURITIES Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Research and Development [Abstract] RESEARCH AGREEMENTS DERIVATIVE LIABILITY Debt Disclosure [Abstract] CONVERTIBLE NOTES PAYABLE LOANS PAYABLE Equity [Abstract] PROMISSORY NOTES, RELATED PARTY Related Party Transactions [Abstract] DUE TO RELATED PARTIES CAPITAL STOCK Income Tax Disclosure [Abstract] INCOME TAXES Commitments and Contingencies Disclosure [Abstract] CONTINGENCIES AND COMMITMENTS Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Principles of Consolidation Use of Estimates Fair Value Measurements Prior Period Reclassifications Stock-Based Compensation Deferred Financing Costs Research and Development Costs Income Taxes Derivative Liability Loss per Common Share Net Loss per Share Applicable to Common Stockholders Recently Issued Accounting Pronouncements Summary of securities were not included in the diluted net loss per share calculation POTENTIALLY DILUTIVE SECURITIES Accounts Payable and Accrued Liabilities Summary of inputs utilized in the final mark to market Summary of share purchase warrants Summary ofderivative liability - warrants and Derivative liability - conversion option Summary of changes in Level 3 liabilities measured at fair value Summary of valuation methodology Debt instrument transactions Summary of share purchase options A status summary of unvested options Share Purchase Warrants Supplemental Cash Flow Elements [Abstract] Summary of income tax provision (benefit) Summary of effects of temporary differences that give rise to significant portions of the deferred tax assets Summary of expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with the actual tax provision (benefit) Number of ovarian cancer patients Percentage of breast cancers Percentage ofof ovarian cancers Liquidity And Financial Condition Details Narrtive Cash and cash equivalents Common stock options Common stock warrants - equity treatment Common stock warrants - liability treatment Convertible notes Excluded potentially dilutive securities Potentially Dilutive Securities Details Potentially dilutive securities Trade accounts payable Share-settled debt Accrued liabilities Employee payroll and severance Accrued interest Total accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities Common stock, Shares issued Trading of shares at fair value Loss on extinguishment Annual license payments Accrued liablities Interest rate on outstanding amounts Dividend yield (per share) Strike price Volatility (annual) Risk-free rate Contractual term (years) Fair value of Conversion Option at extinguishment Contractual Life (Years) Risk free Rate Dividend yield Volatility Derivative liability - warrants Derivative liability - conversion option Total Balance - December 31, 2013 Additions during the year Total unrealized (gains) or losses included in net loss Loss on settlement of debt Change in fair value of conversion option liability Change in fair value of warrant liability Balance - December 31, 2014 Dividend yield (per share) Volatility (annual) Contractual term (years) Issue Date Maturity Date Stated Interest Rate Conversion Terms Principal Balance December 31, 2014 Principal Balance December 31,2013 Total convertible notes Unamortized note discount Total on Balance sheet Convertible notes issued Debt Accrued interest for shares of preferred stock Shares of common stock fair value Loss on extinguishment associated with the note conversions Extinguishment of the derivative liability - conversion option Unsecured loan advances amount Investors converted Related party converted Accrued interest Outstanding principal Outstanding promissory notes Amount of promissory notes repaid Outstanding promissory note amount Related parties note Number of Warrants Balance, December 31, 2013 Issued Cancelled/Forfeited Exercised Extinguished or expired Balance, December 31, 2014 Weighted Average Exercise Price Balance, December 31, 2013 Issued Cancelled/Forfeited Exercised Extinguished or expired Balance, December 31, 2014 Weighted Average Remaining Life Balance, December 31, 2013 Issued Cancelled/Forfeited Exercised Extinguished or expired Balance, December 31, 2014 Number of Shares Unvested, December 31, 2013 Granted Vested Cancelled Unvested, December 31, 2014 Weighted Average Grant-Date Fair Value Unvested, December 31, 2013 Granted Vested Cancelled Unvested, December 31, 2014 Received subscription proceeds1 Received subscription proceeds Preferred stock Shares of common stock Preferred stock value Fair value Related parties converted Accounts payable and loan shares Fair value of approximately Stock based consulting and management fees Incremental fair value Number of outstanding shares of common stock Common stock authorized first Common stock authorized Share issued Excercise price Contractual term Risk free interest rate Dividend yield Annual volatility Intrinsic value of the vested options Expensed portion of value of the granted and vested options Fair value of share purchase warrants Excercise price of warrant Exercise price of placement shares Income Taxes Details Federal: Current Deferred State: Current Deferred Deferred Income Tax Expense (Benefit) Change in valuation allowance Income tax provision (benefit) Deferred tax assets: Net operating loss carryforwards Stock-based compensation Technology licensing fee Total deferred tax assets Valuation allowance Deferred tax assets, net of valuation allowance U.S. federal statutory rate Permanent differences- Non-cash loss on extinguishment of debt Permanent differences-Other permanent differences Unrecognized tax benefits Accrued amount for payment of interest and penalties Federal net operating loss carryforwards Number of post-consolidated shares of common stock Claim for alleged damages Bond payment Amount paid by consultant Interest paid by consultant Unpaid legal fees Award amount Judgment award amount Units of shares purchased by investors Purchase price per share Total purchase price Net of finders’ fee and offering expenses Exercise price of the warrants Maturity term of warrants Percentage of number of shares of common stock sold in the offering to the placement agents Bond payment. Common stock options. Common stock warrants - equity treatment. Common stock warrants - liability treatment. Convertible notes. Excercise price of warrant. Exercise price of placement shares. Fair value derivative liability and conversion option at conversion. Fair value of share purchase warrants. Interest paid by consultant. Exercise price of the warrants. Entire disclosure of loans payable. Maturity term of warrants. Disclosure of accounting policy for net loss per share applicable to common stockholders. Number of post-consolidated shares of common stock. Percentage of breast cancers. Percentage of number of shares of common stock sold in the offering to the placement agents. Percentage ofof ovarian cancers. Permanent differences other permanent differences. Disclosure of accounting policy for prior period reclassifications. Tabular disclosure of Summary of expected tax expense (benefit) based on the U.S. federal statutory rate is reconciled with the actual tax provision (benefit) Assets, Current Deferred Tax Assets, in Process Research and Development Derivative Assets (Liabilities), at Fair Value, Net Loans and Leases Receivable, Gross, Commercial Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Income (Loss) Accretion of Discount Net Income (Loss) Attributable to Parent Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Deferred Policy Acquisition Cost, Foreign Currency Translation Adjustment and Other Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Extinguishment of Debt, Gain (Loss), Income Tax Share-based Compensation Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Deferred Charges Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Repayments of Related Party Debt Repayments of Convertible Debt Net Cash Provided by (Used in) Financing Activities Cash, Period Increase (Decrease) Proceeds from Convertible Debt Increase (Decrease) in Notes Payable, Related Parties PotentiallyDilutiveSecurities Accrued Liabilities, Current Accounts Payable and Accrued Liabilities [Default Label] Accounts Payable and Accrued Liabilities, Noncurrent Derivative Liability, Fair Value, Gross Liability Derivative, Fair Value, Net Financial and Nonfinancial Liabilities, Fair Value Disclosure Increase (Decrease) in Accounts Payable Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term Cancelledforfeited Exercised [Default Label] ExtinguishedOrExpired Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value PreferredStock Common Stock Dividends, Shares Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate Current State and Local Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit)